BACKGROUND: Thrombus resolution is a complex process that involves thrombosis, leukocyte-mediated thrombolysis, and the final resolution of inflammation. Activated protein C (APC) is an anticoagulant that also possesses immunoregulatory activities. AIM: In this study, we sought to examine the effects of APC administration on thrombus resolution using a mouse model of deep vein thrombosis by ligating the inferior vena cava (IVC). METHODS: The IVCs of C57BL/6 mice were ligated. Beginning on day 4 post IVC ligation, mice were injected intraperitoneally daily with APC, APC plus an heme oxygenase-1 (HO-1) inhibitor Sn-protoporphyrin IX (SnPP), SnPP alone, or vehicle control. At different time points following surgery, the thrombus-containing IVCs were weighed and then analyzed by use of biochemical assays and histology. RESULTS: Venous thrombi reached maximum size on day 4 post ligation. The APC-treated group exhibited a significant reduction in thrombus weights on day 12 but not on day 7 compared with control mice. The enhanced thrombus resolution in APC-treated mice correlated with an increased HO-1 expression and a reduced interleukin-6 production. No significant difference was found in urokinase-type plasminogen activator, plasminogen activator inhibitor-1, or matrix metalloproteinase-2 and -9 between APC-treated and control mice. Coinjection of the HO-1 inhibitor SnPP abolished the ability of APC to enhance thrombus resolution. CONCLUSIONS: Our data show that APC enhances the resolution of existing venous thrombi via a mechanism that is in part dependent on HO-1, suggesting that APC could be used as a potential treatment for patients with deep vein thrombosis to accelerate thrombus resolution.
BACKGROUND:Thrombus resolution is a complex process that involves thrombosis, leukocyte-mediated thrombolysis, and the final resolution of inflammation. Activated protein C (APC) is an anticoagulant that also possesses immunoregulatory activities. AIM: In this study, we sought to examine the effects of APC administration on thrombus resolution using a mouse model of deep vein thrombosis by ligating the inferior vena cava (IVC). METHODS: The IVCs of C57BL/6 mice were ligated. Beginning on day 4 post IVC ligation, mice were injected intraperitoneally daily with APC, APC plus an heme oxygenase-1 (HO-1) inhibitor Sn-protoporphyrin IX (SnPP), SnPP alone, or vehicle control. At different time points following surgery, the thrombus-containing IVCs were weighed and then analyzed by use of biochemical assays and histology. RESULTS:Venous thrombi reached maximum size on day 4 post ligation. The APC-treated group exhibited a significant reduction in thrombus weights on day 12 but not on day 7 compared with control mice. The enhanced thrombus resolution in APC-treated mice correlated with an increased HO-1 expression and a reduced interleukin-6 production. No significant difference was found in urokinase-type plasminogen activator, plasminogen activator inhibitor-1, or matrix metalloproteinase-2 and -9 between APC-treated and control mice. Coinjection of the HO-1 inhibitor SnPP abolished the ability of APC to enhance thrombus resolution. CONCLUSIONS: Our data show that APC enhances the resolution of existing venous thrombi via a mechanism that is in part dependent on HO-1, suggesting that APC could be used as a potential treatment for patients with deep vein thrombosis to accelerate thrombus resolution.
Authors: Chunzhang Cao; Yamei Gao; Yang Li; Toni M Antalis; Francis J Castellino; Li Zhang Journal: J Clin Invest Date: 2010-05-10 Impact factor: 14.808
Authors: Tong Cheng; Anthony L Petraglia; Zhang Li; Meenakshisundaram Thiyagarajan; Zhihui Zhong; Zhenhua Wu; Dong Liu; Sanjay B Maggirwar; Rashid Deane; José A Fernández; Barbra LaRue; John H Griffin; Michael Chopp; Berislav V Zlokovic Journal: Nat Med Date: 2006-10-29 Impact factor: 53.440
Authors: Michal J Tracz; Julio P Juncos; Joseph P Grande; Anthony J Croatt; Allan W Ackerman; Zvonimir S Katusic; Karl A Nath Journal: Am J Pathol Date: 2008-11-06 Impact factor: 4.307
Authors: Edward J Kerschen; José A Fernandez; Brian C Cooley; Xia V Yang; Rashmi Sood; Laurent O Mosnier; Francis J Castellino; Nigel Mackman; John H Griffin; Hartmut Weiler Journal: J Exp Med Date: 2007-09-24 Impact factor: 14.307
Authors: Karl A Nath; Joseph P Grande; John D Belcher; Vesna D Garovic; Anthony J Croatt; Matthew L Hillestad; Michael A Barry; Meryl C Nath; Raymond F Regan; Gregory M Vercellotti Journal: Am J Physiol Heart Circ Physiol Date: 2020-01-31 Impact factor: 4.733
Authors: Philipp Blüm; Joachim Pircher; Monika Merkle; Thomas Czermak; Andrea Ribeiro; Hanna Mannell; Florian Krötz; Alexander Hennrich; Michael Spannagl; Simone Köppel; Erik Gaitzsch; Markus Wörnle Journal: Cell Mol Immunol Date: 2016-04-18 Impact factor: 11.530
Authors: Subhradip Mukhopadhyay; Toni M Antalis; Khanh P Nguyen; Mark H Hoofnagle; Rajabrata Sarkar Journal: Blood Date: 2017-03-20 Impact factor: 22.113
Authors: Jeffrey A Kline; Nury M Steuerwald; John A Watts; Mark Courtney; Herbert L Bonkovsky Journal: Thromb Res Date: 2015-08-28 Impact factor: 3.944
Authors: Stacey J Ellery; Madeleine G Goss; Nadine Brew; Hayley Dickinson; Nadia Hale; Domenic A LaRosa; David W Walker; Flora Y Wong Journal: Neurotherapeutics Date: 2019-01 Impact factor: 7.620
Authors: Steven P Grover; Colin E Evans; Ashish S Patel; Bijan Modarai; Prakash Saha; Alberto Smith Journal: Arterioscler Thromb Vasc Biol Date: 2015-12-17 Impact factor: 8.311
Authors: Erik W Martin; Marguerite S Buzza; Kathryn H Driesbaugh; Shihui Liu; Yolanda M Fortenberry; Stephen H Leppla; Toni M Antalis Journal: Oncotarget Date: 2015-10-20
Authors: Subhradip Mukhopadhyay; Tierra A Johnson; Nadire Duru; Marguerite S Buzza; Nisha R Pawar; Rajabrata Sarkar; Toni M Antalis Journal: Front Immunol Date: 2019-06-14 Impact factor: 7.561